Sell Acasti Pharma, says Echelon Wealth
The news is bad for Acasti Pharma (Acasti Pharma Stock...
Search Results for: acasti
Buy Acasti Pharma for a double, Echelon...
Echelon Wealth Partners analyst Douglas Loe is staying bullish on...
Acasti Pharma placed under review by Mackie...
Disappointing results for its lead product candidate CaPre have led...
Acasti Pharma keeps “Top Pick” Status at...
Quebec-based omega-3 drug developer Acasti Pharma (Acasti Pharma Stock Quote,...
Acasti Pharma could have a winner on...
Biopharm company Acasti Pharma (Acasti Pharma Stock Quote, Chart, News...
Acasti Pharma still has more upside, Echelon...
Does Acasti Pharma still have upside? Echelon Wealth Partners analyst...
Acasti Pharma: Time to hop on board,...
With its best-in-class omega-3 drug CaPre currently in Phase III...
Acasti Pharma has a 113 per cent...
Echelon Wealth Partners analyst Douglas Loe is staying put on...